1 Day 2 | 2020 ASH Annual Meeting Conference Coverage
Advertisement
Home Day 2

Day 2

More Than Half of Patients with PNH Are Receiving Higher Than Recommended Doses of...

Patients with paroxysmal nocturnal hemoglobinuria (PNH) are often treated with C5 complement inhibitors, such as eculizumab. The standard dosage of eculizumab, administered...

Reducing Financial Toxicity for Patients with Cancer Improves Quality of Life

Financial toxicity is associated with increased morbidity and mortality in patients with cancer. A pilot study found that using a financial toxicity...

COVID-19 Morbidity and Mortality in Patients with Hematologic Malignancies

A study presented at the 2020 ASH Annual Meeting found that patients with hematologic malignancies experience significant morbidity and mortality from COVID-19...

Pegcetacoplan Versus Eculizumab for Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, clonal, non-malignant hematologic disease characterized by complement-mediated red blood cell hemolysis, and the current...
Advertisement
Advertisement